Blitz Bureau
NEW DELHI: In a significant development, the Indian Council of Medical Research (ICMR) and Panacea Biotec on August 14 announced they have started first-ever Phase 3 clinical trial for developing a dengue vaccine in India. The landmark trial will evaluate the efficacy of India’s indigenous tetravalent dengue vaccine, DengiAll, developed by Panacea Biotec.
The first participant in this trial was vaccinated at Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences (PGIMS), Rohtak, according to the Ministry of Health and Family Welfare. “The initiation of this Phase 3 clinical trial for India’s first indigenous dengue vaccine marks a critical advancement in our fight against dengue. It reflects our commitment to protecting our citizens from this pervasive disease and underscores India’s capabilities in vaccine research and development,” said JP Nadda, Union Minister of Health and Family Welfare.
Through this collaboration between ICMR and Panacea Biotec, “we are not only taking a step towards ensuring the health and well-being of our people but also reinforcing our vision of Atmanirbhar Bharat in the healthcare sector,” Nadda said.
In collaboration with ICMR, Panacea Biotec will conduct the Phase 3 clinical trial across 19 sites in 18 states and union territories, involving more than 10,335 healthy adult participants. The trial, primarily funded by ICMR with partial support from Panacea Biotec, is set to follow up with participants for two years. At the moment, there is no antiviral treatment or licensed vaccine against dengue in the country.
According to the government, the development of an effective vaccine is complex due to the need to achieve good efficacy for all four serotypes.
